{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:27:33Z","timestamp":1792016853936,"version":"4.4.0"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Optic neuritis (ON) and neuromyelitis optica spectrum disorders (NMOSD) are inflammatory neuro-ophthalmological conditions characterized by significant visual impairment and diverse clinical manifestations. Advances in diagnostic biomarkers have improved disease identification, including aquaporin-4 immunoglobulin G (AQP4-IgG) and myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG). However, some patients remain biomarker-negative, complicating differential diagnosis and personalized treatment. Multi-omics approaches have provided valuable insights into critical molecular pathways, novel biomarkers, and the shared and distinct features of ON and NMOSD. This review highlights recent advancements in biomarker research for ON and NMOSD, emphasizes the potential of multi-omics integration, identifies existing challenges, and proposes future research directions. These findings aim to enhance diagnostic accuracy, improve prognostic capabilities, and support the development of precision medicine strategies for ON and NMOSD.<\/jats:p>","DOI":"10.3389\/fneur.2025.1559172","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T04:16:22Z","timestamp":1746504982000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Advances in biomarkers for optic neuritis and neuromyelitis optica spectrum disorders: a multi-omics perspective"],"prefix":"10.3389","volume":"16","author":[{"given":"Lidong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1038\/s41433-023-02477-0","article-title":"The neuro-ophthalmological manifestations of NMOSD and MOGAD\u2014a comprehensive review","volume":"37","author":"Moheb","year":"2023","journal-title":"Eye."},{"key":"B2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1590\/0004-282x20170121","article-title":"MOG-IgG associated optic neuritis is not multiple sclerosis","volume":"75","author":"Costa","year":"2017","journal-title":"Arq Neuropsiquiatr."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1016\/j.csbj.2021.04.060","article-title":"Computational strategies for single-cell multi-omics integration","volume":"19","author":"Adossa","year":"2021","journal-title":"Comput Struct Biotechnol J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/cen3.12354","article-title":"Clinical characteristics of autoimmune optic neuritis","volume":"8","author":"Kawachi","year":"2017","journal-title":"Clin Exper Neuroimmunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2055217318791196","DOI":"10.1177\/2055217318791196","article-title":"Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis","volume":"4","author":"Srikajon","year":"2018","journal-title":"Mult Scler J Exper Transl Clin."},{"key":"B6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.msard.2013.11.003","article-title":"The role of imaging in diagnosing neuromyelitis optica spectrum disorder","volume":"3","author":"Matthews","year":"2014","journal-title":"Mult Scler Relat Disord."},{"key":"B7","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/biom12040591","article-title":"Aquaporin-4 in neuromyelitis optica spectrum disorders: a target of autoimmunity in the central nervous system","volume":"12","author":"Abe","year":"2022","journal-title":"Biomolecules."},{"key":"B8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.3390\/ijms23084154","article-title":"Adverse events in NMOSD therapy","volume":"23","author":"Giglhuber","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1002\/acn3.51147","article-title":"Genetic factors for susceptibility to and manifestations of neuromyelitis optica","volume":"7","author":"Matsushita","year":"2020","journal-title":"Ann Clin Transl Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1038\/s41467-020-16625-7","article-title":"Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica","volume":"11","author":"Agasing","year":"2020","journal-title":"Nat Commun."},{"key":"B12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/01.nrl.0000253065.31662.37","article-title":"The pathology of MS: new insights and potential clinical applications","volume":"13","author":"Pittock","year":"2007","journal-title":"Neurologist."},{"key":"B13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nri.2016.123","article-title":"Cytokine networks in neuroinflammation","volume":"17","author":"Becher","year":"2017","journal-title":"Nat Rev Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1212\/CON.0000000000000768","article-title":"Optic neuritis","volume":"25","author":"Bennett","year":"2019","journal-title":"Continuum."},{"key":"B15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/EB.S69173","article-title":"Infectious optic neuropathies: a clinical update","volume":"7","author":"Kahloun","year":"2015","journal-title":"Eye Brain."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11910-019-1014-z","article-title":"Clinical characteristics and treatment of MOG-IgG\u2013associated optic neuritis","volume":"19","author":"Tajfirouz","year":"2019","journal-title":"Curr Neurol Neurosci Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","article-title":"MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder","volume":"25","author":"Narayan","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41582-021-00568-8","article-title":"Hope for patients with neuromyelitis optica spectrum disorders\u2014from mechanisms to trials","volume":"17","author":"Pittock","year":"2021","journal-title":"Nat Rev Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J Neuroinflammation."},{"key":"B22","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/jnnp.57.5.544","article-title":"Autoimmune T cell repertoire in optic neuritis and multiple sclerosis: T cells recognising multiple myelin proteins are accumulated in cerebrospinal fluid","volume":"57","author":"S\u00f6derstr\u00f6m","year":"1994","journal-title":"J Neurol Neurosur Psychiat."},{"key":"B23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41433-020-01288-x","article-title":"Optical coherence tomography (OCT) in neuro-ophthalmology","volume":"35","author":"Minakaran","year":"2021","journal-title":"Eye."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.22336\/rjo.2018.2","article-title":"The role of Optical Coherence Tomography in optic neuropathies","volume":"62","author":"Iorga","year":"2018","journal-title":"Roman J Ophthalmol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/08820538.2020.1866027","article-title":"MRI characteristics of NMO, MOG and MS related optic neuritis","author":"Winter","year":"2020","journal-title":"Seminars in Ophthalmology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3892\/ijmm_00000416","article-title":"Alteration of T helper cell subsets in the optic nerve of experimental autoimmune encephalomyelitis","volume":"25","author":"Tian","year":"2010","journal-title":"Int J Mol Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e841","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurology."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e72399","DOI":"10.1371\/journal.pone.0072399","article-title":"Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases","volume":"8","author":"Wullschleger","year":"2013","journal-title":"PLoS ONE."},{"key":"B29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11481-011-9287-2","article-title":"Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system","volume":"7","author":"Montgomery","year":"2012","journal-title":"J Neuroim Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.immuni.2009.09.002","article-title":"Cross-regulation of signaling pathways by interferon-\u03b3: implications for immune responses and autoimmune diseases","volume":"31","author":"Hu","year":"2009","journal-title":"Immunity."},{"key":"B31","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s00415-015-7983-1","article-title":"Isolated new onset \u2018atypical'optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up","volume":"263","author":"Piccolo","year":"2016","journal-title":"J Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"540156","DOI":"10.3389\/fneur.2020.540156","article-title":"AQP4-IgG and MOG-IgG related optic neuritis\u2014prevalence, optical coherence tomography findings, and visual outcomes: a systematic review and meta-analysis","volume":"11","author":"Filippatou","year":"2020","journal-title":"Front Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0170847","DOI":"10.1371\/journal.pone.0170847","article-title":"Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study","volume":"12","author":"Stiebel-Kalish","year":"2017","journal-title":"PLoS ONE."},{"key":"B34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.survophthal.2019.08.001","article-title":"Optic neuritis in the era of biomarkers","volume":"65","author":"Chen","year":"2020","journal-title":"Surv Ophthalmol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"20552173211052656","DOI":"10.1177\/20552173211052656","article-title":"Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders","volume":"7","author":"Redenbaugh","year":"2021","journal-title":"Mult Scler J\u2013Exper Transl Clin."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1212\/NXI.0000000000000231","article-title":"Clinical utility of testing AQP4-IgG in CSF: guidance for physicians","volume":"3","author":"Majed","year":"2016","journal-title":"Neuroimmunol Neuroinflam."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1177\/1352458512443917","article-title":"Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica","volume":"18","author":"Isobe","year":"2012","journal-title":"Mult Scler J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1212\/WNL.0000000000206805","article-title":"Should We test for IgG Antibodies Against MOG in Both Serum and CSF in Patients With Suspected MOGAD?","volume":"100","author":"Kim","year":"2023","journal-title":"Neurology."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1415535","DOI":"10.3389\/fneur.2024.1415535","article-title":"Soluble biomarkers for neuromyelitis optica spectrum disorders: a mini review","volume":"15","author":"Rodin","year":"2024","journal-title":"Front Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/1744666X.2023.2148657","article-title":"Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review","volume":"19","author":"Schindler","year":"2023","journal-title":"Expert Rev Clin Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"853891","DOI":"10.3389\/fimmu.2022.853891","article-title":"Plasma complement 3 and complement 4 are promising biomarkers for distinguishing NMOSD from MOGAD and are associated with the blood-brain-barrier disruption in NMOSD","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1090548","DOI":"10.3389\/fimmu.2023.1090548","article-title":"Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders","volume":"14","author":"Miyamoto","year":"2023","journal-title":"Front Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1080\/14712598.2021.1884223","article-title":"Targeting the complement system in neuromyelitis optica spectrum disorder","volume":"21","author":"Asavapanumas","year":"2021","journal-title":"Expert Opin Biol Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e61835","DOI":"10.1371\/journal.pone.0061835","article-title":"Characteristic cerebrospinal fluid cytokine\/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis","volume":"8","author":"Matsushita","year":"2013","journal-title":"PLoS ONE."},{"key":"B46","doi-asserted-by":"publisher","first-page":"151959","DOI":"10.1016\/j.imbio.2020.151959","article-title":"Correlation between serum levels of endothelin-1 and disease severity in patients with neuromyelitis optica spectrum disorders","volume":"225","author":"Yi","year":"2020","journal-title":"Immunobiology."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1418309","DOI":"10.3389\/fimmu.2024.1418309","article-title":"The levels of circulating cytokines and risk of neuromyelitis optica spectrum disorder: a Mendelian randomization study","volume":"15","author":"Ma","year":"2024","journal-title":"Front Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000464135","article-title":"Cytokine and chemokine profiles in patients with neuromyelitis optica spectrum disorder","volume":"23","author":"Wang","year":"2017","journal-title":"Neuroimmunomodulation."},{"key":"B49","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/jcm13010010","article-title":"Optic neuritis: the influence of gene polymorphisms and serum levels of STAT4 (rs10181656, rs7574865, rs7601754, rs10168266)","volume":"13","author":"Gedvilaite","year":"2023","journal-title":"J Clin Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.21608\/mjcu.2023.305914","article-title":"Association of IL-7Ra gene polymorphisms and serum interleukin 7 levels with multiple sclerosis and neuromyelitis optica in Egyptian patients","volume":"91","author":"Mostafa","year":"2023","journal-title":"Med J Cairo Univ."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3390\/genes14071319","article-title":"Genetic basis of inflammatory demyelinating diseases of the central nervous system: multiple sclerosis and neuromyelitis optica spectrum","volume":"14","author":"Ortiz","year":"2023","journal-title":"Genes."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.3390\/biomedicines11082209","article-title":"Genome-wide expression profile in people with optic neuritis associated with multiple sclerosis","volume":"11","author":"Habek","year":"2023","journal-title":"Biomedicines."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1136\/bjo.2003.040980","article-title":"Optic neuritis: chemokine receptor CXCR3 and its ligands","volume":"88","author":"S\u00f8rensen","year":"2004","journal-title":"Br J Ophthalmol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1007\/s00415-023-11920-x","article-title":"An update on optic neuritis","volume":"270","author":"Kraker","year":"2023","journal-title":"J Neurol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1177\/1352458519864928","article-title":"Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning","volume":"26","author":"Sotirchos","year":"2019","journal-title":"Mult Scler"},{"key":"B56","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/jnnp-2022-330412","article-title":"Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder","volume":"94","author":"Aktas","year":"2023","journal-title":"J Neurol Neurosurg Psychiat."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e0274565","DOI":"10.1371\/journal.pone.0274565","article-title":"Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: a systematic review and meta-analysis","volume":"17","author":"Ning","year":"2022","journal-title":"PLoS ONE."},{"key":"B58","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jpba.2018.02.015","article-title":"Target and untargeted GC\u2013MS based metabolomic study of mouse optic nerve and its potential in the study of neurological visual diseases","volume":"153","author":"Gonzalez-Riano","year":"2018","journal-title":"J Pharm Biomed Anal."},{"key":"B59","doi-asserted-by":"publisher","first-page":"106306","DOI":"10.1016\/j.nbd.2023.106306","article-title":"Glutamate transporter contribution to retinal ganglion cell vulnerability in a rat model of multiple sclerosis","volume":"187","author":"Boccuni","year":"2023","journal-title":"Neurobiol Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mmr.2023.13065","article-title":"Metabolomic profiling of a neurodegenerative retina following optic nerve transection","volume":"28","author":"Zhu","year":"2023","journal-title":"Mol Med Rep."},{"key":"B61","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.3390\/cells11213439","article-title":"The DNA methylation in neurological diseases","volume":"11","author":"Younesian","year":"2022","journal-title":"Cells."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1423584","DOI":"10.3389\/fgene.2024.1423584","article-title":"Brief research report: WGCNA-driven identification of histone modification genes as potential biomarkers in AQP4-Associated optic neuritis","volume":"15","author":"Cao","year":"2024","journal-title":"Front Genet."},{"key":"B63","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s12017-017-8463-9","article-title":"STAT4 polymorphisms are associated with neuromyelitis optica spectrum disorders","volume":"19","author":"Shi","year":"2017","journal-title":"Neuromolecular Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2387414","DOI":"10.1080\/08916934.2024.2387414","article-title":"HLA-transgenic mouse models to study autoimmune central nervous system diseases","volume":"57","author":"Pressley","year":"2024","journal-title":"Autoimmunity."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3389\/fimmu.2020.01064","article-title":"Different exosomal microRNA profile in aquaporin-4 antibody positive neuromyelitis optica spectrum disorders","volume":"11","author":"Chen","year":"2020","journal-title":"Front Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"106156","DOI":"10.1016\/j.msard.2024.106156","article-title":"Interleukin-6 inhibitors for neuromyelitis optica spectrum disorder (NMOSD): a systematic review and meta-analysis","author":"Noll","year":"2024","journal-title":"Mult Scler Relat Disord."},{"key":"B67","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000494976","article-title":"Cytokines and tissue damage biomarkers in first-onset neuromyelitis optica spectrum disorders: significance of interleukin-6","volume":"25","author":"Wei","year":"2019","journal-title":"Neuroimmunomodulation."},{"key":"B68","doi-asserted-by":"publisher","first-page":"e852","DOI":"10.1212\/NXI.0000000000000852","article-title":"High-throughput investigation of molecular and cellular biomarkers in NMOSD","volume":"7","author":"Yandamuri","year":"2020","journal-title":"Neurology."},{"key":"B69","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1136\/jnnp-2022-330707","article-title":"Anti-Argonaute antibodies as a potential biomarker in NMOSD","volume":"94","author":"Carta","year":"2023","journal-title":"J Neurol Neurosurg Psychiat."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3390\/medicina60071050","article-title":"The role of glial fibrillary acidic protein as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"60","author":"Shaygannejad","year":"2024","journal-title":"Medicina."},{"key":"B71","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.cca.2016.09.001","article-title":"Exosomal proteome analysis of cerebrospinal fluid detects biosignatures of neuromyelitis optica and multiple sclerosis","volume":"462","author":"Lee","year":"2016","journal-title":"Clin Chim Acta."},{"key":"B72","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3390\/metabo10090374","article-title":"Metabolomic profiling in neuromyelitis optica spectrum disorder biomarker discovery","volume":"10","author":"Thoman","year":"2020","journal-title":"Metabolites."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1042\/BST20140164","article-title":"Hypercholesterolaemia-induced oxidative stress at the blood\u2013brain barrier","volume":"42","author":"Dias","year":"2014","journal-title":"Biochem Soc Trans."},{"key":"B74","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/nan.12757","article-title":"Neurodegenerative movement disorders: an epigenetics perspective and promise for the future","volume":"47","author":"Murthy","year":"2021","journal-title":"Neuropathol Appl Neurobiol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.3390\/ijms23105801","article-title":"Histone modifications and non-coding RNAs: mutual epigenetic regulation and role in pathogenesis","volume":"23","author":"Bure","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/biom14070735","article-title":"Concept of normativity in multi-omics analysis of axon regeneration","volume":"14","author":"Moceri","year":"2024","journal-title":"Biomolecules."},{"key":"B77","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1186\/s12967-024-05801-8","article-title":"Integrated omics profiling reveals systemic dysregulation and potential biomarkers in the blood of patients with neuromyelitis optica spectrum disorders","volume":"22","author":"Xie","year":"2024","journal-title":"J Transl Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"e69038","DOI":"10.7759\/cureus.69038","article-title":"Emerging biomarkers for the early detection of autoimmune encephalitis: a narrative review","volume":"16","author":"Bokhari","year":"2024","journal-title":"Cureus."},{"key":"B79","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1021\/acsmeasuresciau.3c00067","article-title":"A look into ocular diseases: the pivotal role of omics sciences in ophthalmology research","volume":"4","author":"Fucito","year":"2024","journal-title":"ACS Measur Sci Au."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1422939","DOI":"10.3389\/fpsyt.2024.1422939","article-title":"Omics approaches open new horizons in major depressive disorder: from biomarkers to precision medicine","volume":"15","author":"Stolfi","year":"2024","journal-title":"Front Psychiatry."},{"key":"B81","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-024-01596-9","article-title":"Spatial multi-omics: deciphering technological landscape of integration of multi-omics and its applications","volume":"17","author":"Liu","year":"2024","journal-title":"J Hematol Oncol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e200188","DOI":"10.1212\/NXI.0000000000200188","article-title":"Serum biomarker profiles discriminate AQP4 seropositive and double seronegative neuromyelitis optica spectrum disorder","volume":"11","author":"Carta","year":"2023","journal-title":"Neurology."},{"key":"B83","doi-asserted-by":"publisher","first-page":"109761","DOI":"10.1016\/j.intimp.2023.109761","article-title":"Decipher potential biomarkers of diagnosis and disease activity for NMOSD with AQP4 using LC-MS\/MS and Simoa","volume":"116","author":"Wang","year":"2023","journal-title":"Int Immunopharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"10","DOI":"10.17925\/USN.2024.20.1.3","article-title":"Recent advances on the diagnosis and management of seronegative neuromyelitis optica spectrum disorder","volume":"20","author":"Elisa Marin","year":"2024","journal-title":"touchREVIEWS Neurol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s10072-023-06617-y","article-title":"Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysis","volume":"44","author":"Bagherieh","year":"2023","journal-title":"Neurol Sci."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.3390\/biomedicines12071496","article-title":"Navigating challenges and opportunities in multi-omics integration for personalized healthcare","volume":"12","author":"Mohr","year":"2024","journal-title":"Biomedicines."},{"key":"B87","doi-asserted-by":"publisher","first-page":"610798","DOI":"10.3389\/fgene.2020.610798","article-title":"State of the field in multi-omics research: from computational needs to data mining and sharing","volume":"11","author":"Krassowski","year":"2020","journal-title":"Front Genet."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.4103\/NRR.NRR-D-24-00109","article-title":"Biomarkers for neuromyelitis optica: a visual analysis of emerging research trends","volume":"19","author":"Li","year":"2024","journal-title":"Neural Regener Res."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1559172\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T04:16:23Z","timestamp":1746504983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1559172\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":88,"alternative-id":["10.3389\/fneur.2025.1559172"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1559172","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"article-number":"1559172"}}